Suppr超能文献

复发性或持续性肛门鳞状细胞癌的挽救性治疗:多模态治疗的作用。

Salvage Treatment of Recurrent or Persistent Anal Squamous Cell Carcinoma: The Role of Multi-modality Therapy.

机构信息

University of Texas McGovern Medical School, Houston, TX.

Department of Gastrointestinal Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.

出版信息

Clin Colorectal Cancer. 2024 Mar;23(1):85-94. doi: 10.1016/j.clcc.2023.12.002. Epub 2023 Dec 13.

Abstract

BACKGROUND

The standard treatment for recurrent or persistent anal squamous cell carcinoma is surgical salvage, but disease control and survival are suboptimal.

PATIENTS/METHODS: Patients treated for recurrent or persistent anal squamous cell carcinoma at our institution from 2002 to 2022 were included. Patients were classified by type of salvage treatment received: surgery alone vs. reirradiation followed by surgery and by whether they received intraoperative radiation at the time of surgery. Clinical and pathologic variables were collected and assessed for association with risk of second local recurrence and death from any cause.

RESULTS

Sixty four patients were included; 55(85.9%) were treated with surgery alone and 9 (14.1%) were treated with reirradiation followed by surgery. Median (IQR) follow up from the time of salvage treatment was 40.0 (20.3-68.0) months. The 3-year cumulative incidence of second local recurrence (95% CI) after salvage surgery was 36% (24%-48%); 39% (26%-52%) for patients treated with surgery alone and 15% (0.46%-51%) for patients treated with reirradiation followed by surgery. Factors associated with increased second local recurrence after salvage surgery included a locoregional recurrence, lymphovascular space invasion and positive surgical margins. The 3-year overall survival (95% CI) after salvage surgery was 70% (59%-83%); 68% (7%-56%) after surgery alone and 89% (10.5%-70.6%) after reirradiation followed by surgery. Factors associated with worse overall survival included male sex, a larger recurrent tumor and positive surgical margins.

CONCLUSIONS

Approximately 60% of patients achieved pelvic control after salvage therapy for recurrent or persistent anal squamous cell carcinoma. Although receipt of reirradiation and intraoperative radiation were not associated with improved second local recurrence or overall survival in our cohort, patients with positive surgical margins and lymphovascular space invasion on surgical pathology had higher rates of pelvic recurrence after salvage surgery and may benefit from escalated salvage therapy.

摘要

背景

复发性或持续性肛门鳞癌的标准治疗方法是手术挽救,但疾病控制和生存率不理想。

患者/方法:本研究纳入了 2002 年至 2022 年期间在我院接受复发性或持续性肛门鳞癌治疗的患者。根据接受的挽救治疗类型对患者进行分类:单纯手术与再放疗后手术,以及手术时是否接受术中放疗。收集并评估临床和病理变量与第二次局部复发和任何原因死亡的风险之间的关系。

结果

共纳入 64 例患者;55 例(85.9%)接受单纯手术治疗,9 例(14.1%)接受再放疗后手术治疗。从挽救治疗时起的中位(IQR)随访时间为 40.0(20.3-68.0)个月。挽救手术后 3 年的第二次局部复发累积发生率(95%CI)为 36%(24%-48%);单纯手术组为 39%(26%-52%),再放疗后手术组为 15%(0.46%-51%)。挽救手术后局部复发增加的相关因素包括局部区域复发、脉管侵犯和切缘阳性。挽救手术后 3 年的总生存率(95%CI)为 70%(59%-83%);单纯手术组为 68%(7%-56%),再放疗后手术组为 89%(10.5%-70.6%)。总生存率较差的相关因素包括男性、较大的复发性肿瘤和切缘阳性。

结论

约 60%的复发性或持续性肛门鳞癌患者在挽救治疗后获得盆腔控制。尽管在本队列中,再放疗和术中放疗的应用与第二次局部复发或总生存率的改善无关,但在手术病理中具有切缘阳性和脉管侵犯的患者在挽救手术后盆腔复发率更高,可能受益于强化挽救治疗。

相似文献

本文引用的文献

1
Cancer statistics, 2023.癌症统计数据,2023 年。
CA Cancer J Clin. 2023 Jan;73(1):17-48. doi: 10.3322/caac.21763.
4

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验